Cannabidiol en pacientes con epilepsia

Referencias bibliográficas:

1 Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 2007; 4: 1614–48.

2 Gowers W. Epilepsy and other chronic convulsive disorders. London: Churchill, 1881.

3 Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004; 62: 2095–97.

4 Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis 2007; 4: 103–06.

5 Hill A, Hill T, Whalley B. The development of cannabinoid based therapies for epilepsy. In: Murillo-Rodriguez E, Onaivi ES, Darmani NA, Wagner E, eds. Endocannabinoids: molecular, pharmacological, behavioral and clinical features. Oak Park, IL: Bentham Science, 2013: 164–204.

6 Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Eng J Med 2014; 370: 2219–27.

7 Porter BE, Jacobson C. Report of a parent survey of cannabidiol enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013; 29: 574–77.

8 Gupta S. Why I changed my mind on weed. Aug 9, 2013.

 http://edition.cnn.com/2013/08/08/health/gupta-changed-mindmarijuana/ index.html (accessed Nov 1, 2015).

9 Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014; 55: 783–86.

10 Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014; 55: 791–802.

11 Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; 3: CD009270.

12 Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82: 1556–63.

13 Wade DT, Makela P, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639–45.

14 Panelli RJ, Kilpatrick C, Moore SM, Matkovic Z, D’Souza WJ, O’Brien TJ. The Liverpool Adverse Events Profile le: relation to AED use and mood. Epilepsia 2007; 48: 456–63.